JSPR
Price
$0.63
Change
+$0.01 (+1.61%)
Updated
Jul 31 closing price
Capitalization
20.96M
5 days until earnings call
Intraday BUY SELL Signals
NXTC
Price
$4.14
Change
-$0.89 (-17.69%)
Updated
Jul 31 closing price
Capitalization
16.87M
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

JSPR vs NXTC

JSPR vs NXTC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
JSPR vs. NXTC commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JSPR is a Hold and NXTC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (JSPR: $0.63 vs. NXTC: $4.14)
Brand notoriety: JSPR and NXTC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JSPR: 31% vs. NXTC: 30%
Market capitalization -- JSPR: $20.96M vs. NXTC: $16.87M
JSPR [@Biotechnology] is valued at $20.96M. NXTC’s [@Biotechnology] market capitalization is $16.87M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JSPR’s FA Score shows that 1 FA rating(s) are green whileNXTC’s FA Score has 1 green FA rating(s).

  • JSPR’s FA Score: 1 green, 4 red.
  • NXTC’s FA Score: 1 green, 4 red.
According to our system of comparison, JSPR is a better buy in the long-term than NXTC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JSPR’s TA Score shows that 5 TA indicator(s) are bullish while NXTC’s TA Score has 4 bullish TA indicator(s).

  • JSPR’s TA Score: 5 bullish, 5 bearish.
  • NXTC’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, JSPR is a better buy in the short-term than NXTC.

Price Growth

JSPR (@Biotechnology) experienced а -8.48% price change this week, while NXTC (@Biotechnology) price change was -2.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.22%. For the same industry, the average monthly price growth was -8.12%, and the average quarterly price growth was +2790.29%.

Reported Earning Dates

JSPR is expected to report earnings on Aug 07, 2026.

NXTC is expected to report earnings on Aug 03, 2026.

Industries' Descriptions

@Biotechnology (-1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JSPR($21M) has a higher market cap than NXTC($16.9M). JSPR YTD gains are higher at: -65.574 vs. NXTC (-70.789). NXTC has higher annual earnings (EBITDA): -54.29M vs. JSPR (-72.24M). NXTC has more cash in the bank: 29.7M vs. JSPR (14.1M). JSPR has less debt than NXTC: JSPR (757K) vs NXTC (3.88M). JSPR (0) and NXTC (0) have equivalent revenues.
JSPRNXTCJSPR / NXTC
Capitalization21M16.9M124%
EBITDA-72.24M-54.29M133%
Gain YTD-65.574-70.78993%
P/E RatioN/AN/A-
Revenue00-
Total Cash14.1M29.7M47%
Total Debt757K3.88M20%
FUNDAMENTALS RATINGS
JSPR vs NXTC: Fundamental Ratings
JSPR
NXTC
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
13
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6338
P/E GROWTH RATING
1..100
5100
SEASONALITY SCORE
1..100
n/a42

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NXTC's Valuation (13) in the Biotechnology industry is in the same range as JSPR (44) in the null industry. This means that NXTC’s stock grew similarly to JSPR’s over the last 12 months.

NXTC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as JSPR (100) in the null industry. This means that NXTC’s stock grew similarly to JSPR’s over the last 12 months.

NXTC's SMR Rating (100) in the Biotechnology industry is in the same range as JSPR (100) in the null industry. This means that NXTC’s stock grew similarly to JSPR’s over the last 12 months.

NXTC's Price Growth Rating (38) in the Biotechnology industry is in the same range as JSPR (63) in the null industry. This means that NXTC’s stock grew similarly to JSPR’s over the last 12 months.

JSPR's P/E Growth Rating (5) in the null industry is significantly better than the same rating for NXTC (100) in the Biotechnology industry. This means that JSPR’s stock grew significantly faster than NXTC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JSPRNXTC
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 6 days ago
79%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 11 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
JSPR
Daily Signal:
Gain/Loss:
NXTC
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLB49.590.68
+1.39%
SLB Limited
PAGP26.330.16
+0.62%
Plains GP Holdings LP
FF4.95-0.02
-0.40%
Future Fuel Corp
UPBD19.39-0.73
-3.63%
Upbound Group
SOS0.92-0.04
-3.97%
SOS Limited

JSPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, JSPR has been loosely correlated with AUPH. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if JSPR jumps, then AUPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JSPR
1D Price
Change %
JSPR100%
+1.48%
AUPH - JSPR
44%
Loosely correlated
-0.80%
FRMM - JSPR
38%
Loosely correlated
-3.91%
NXTC - JSPR
36%
Loosely correlated
-17.59%
IMRX - JSPR
34%
Loosely correlated
-2.36%
OCS - JSPR
33%
Loosely correlated
+0.89%
More